S&P 500   4,330.66 (+0.25%)
DOW   33,962.27 (+0.00%)
QQQ   358.64 (+0.20%)
AAPL   175.47 (+0.39%)
MSFT   316.59 (-0.13%)
META   300.00 (+0.31%)
GOOGL   130.80 (+0.42%)
AMZN   131.27 (+1.67%)
TSLA   245.74 (+0.35%)
NVDA   419.36 (+0.78%)
NIO   8.35 (-2.11%)
BABA   87.03 (-1.44%)
AMD   96.98 (+0.81%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.35 (-0.77%)
CGC   0.93 (+10.43%)
GE   111.57 (+0.29%)
DIS   80.83 (-0.52%)
AMC   8.19 (+7.48%)
PFE   32.85 (+0.49%)
PYPL   58.80 (+1.59%)
NFLX   384.08 (+1.12%)
S&P 500   4,330.66 (+0.25%)
DOW   33,962.27 (+0.00%)
QQQ   358.64 (+0.20%)
AAPL   175.47 (+0.39%)
MSFT   316.59 (-0.13%)
META   300.00 (+0.31%)
GOOGL   130.80 (+0.42%)
AMZN   131.27 (+1.67%)
TSLA   245.74 (+0.35%)
NVDA   419.36 (+0.78%)
NIO   8.35 (-2.11%)
BABA   87.03 (-1.44%)
AMD   96.98 (+0.81%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.35 (-0.77%)
CGC   0.93 (+10.43%)
GE   111.57 (+0.29%)
DIS   80.83 (-0.52%)
AMC   8.19 (+7.48%)
PFE   32.85 (+0.49%)
PYPL   58.80 (+1.59%)
NFLX   384.08 (+1.12%)
S&P 500   4,330.66 (+0.25%)
DOW   33,962.27 (+0.00%)
QQQ   358.64 (+0.20%)
AAPL   175.47 (+0.39%)
MSFT   316.59 (-0.13%)
META   300.00 (+0.31%)
GOOGL   130.80 (+0.42%)
AMZN   131.27 (+1.67%)
TSLA   245.74 (+0.35%)
NVDA   419.36 (+0.78%)
NIO   8.35 (-2.11%)
BABA   87.03 (-1.44%)
AMD   96.98 (+0.81%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.35 (-0.77%)
CGC   0.93 (+10.43%)
GE   111.57 (+0.29%)
DIS   80.83 (-0.52%)
AMC   8.19 (+7.48%)
PFE   32.85 (+0.49%)
PYPL   58.80 (+1.59%)
NFLX   384.08 (+1.12%)
S&P 500   4,330.66 (+0.25%)
DOW   33,962.27 (+0.00%)
QQQ   358.64 (+0.20%)
AAPL   175.47 (+0.39%)
MSFT   316.59 (-0.13%)
META   300.00 (+0.31%)
GOOGL   130.80 (+0.42%)
AMZN   131.27 (+1.67%)
TSLA   245.74 (+0.35%)
NVDA   419.36 (+0.78%)
NIO   8.35 (-2.11%)
BABA   87.03 (-1.44%)
AMD   96.98 (+0.81%)
T   15.07 (-0.33%)
F   12.56 (+1.05%)
MU   68.35 (-0.77%)
CGC   0.93 (+10.43%)
GE   111.57 (+0.29%)
DIS   80.83 (-0.52%)
AMC   8.19 (+7.48%)
PFE   32.85 (+0.49%)
PYPL   58.80 (+1.59%)
NFLX   384.08 (+1.12%)
NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Forecast, Price & News

$1.28
+0.00 (+0.27%)
(As of 03:28 PM ET)
Compare
Today's Range
$1.27
$1.31
50-Day Range
$1.27
$1.76
52-Week Range
$0.76
$2.14
Volume
23,825 shs
Average Volume
46,652 shs
Market Capitalization
$25.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Regulus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
708.9% Upside
$10.50 Price Target
Short Interest
Healthy
1.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Regulus Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.52) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

299th out of 961 stocks

Pharmaceutical Preparations Industry

124th out of 456 stocks


RGLS stock logo

About Regulus Therapeutics (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

RGLS Price History

RGLS Stock News Headlines

Space CEO Featured on Good Morning America
A $25 Billion Earth Observation Market by 2040. Learn more
Analyst Expectations for Regulus Therapeutics's Future
Space CEO Featured on Good Morning America
A $25 Billion Earth Observation Market by 2040. Learn more
Regulus Therapeutics (NASDAQ:RGLS) Given Buy Rating at HC Wainwright
Regulus (RGLS) Gets a Buy from H.C. Wainwright
Expert Ratings for Regulus Therapeutics
H.C. Wainwright Remains a Buy on Regulus (RGLS)
Regulus Therapeutics (NASDAQ: RGLS)
See More Headlines
Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Company Calendar

Last Earnings
8/08/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGLS
CUSIP
75915K10
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+720.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.01 million
Book Value
$2.27 per share

Miscellaneous

Free Float
17,845,000
Market Cap
$24.93 million
Optionable
Optionable
Beta
1.65
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Joseph P. Hagan M.B.A.Mr. Joseph P. Hagan M.B.A. (Age 54)
    CEO & Director
    Comp: $920.73k
  • Ms. Crispina Calsada CPA (Age 53)
    Chief Financial Officer
    Comp: $500.87k
  • Mr. Christopher Ray Aker J.D.Mr. Christopher Ray Aker J.D. (Age 62)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $524.79k
  • Dr. Preston S. Klassen M.D. (Age 54)
    M.H.S., Pres and Head of R&D
  • Mr. Daniel J. Penksa (Age 37)
    Exec. Director of Fin. & Controller
  • Dr. Claire Susan Padgett M.S.
    M.T., Ph.D., Sr. VP of Clinical Operations
  • Dr. Rekha Garg M.D.
    M.S., Sr. VP of Clinical Devel. & Regulatory













RGLS Stock - Frequently Asked Questions

Should I buy or sell Regulus Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGLS shares.
View RGLS analyst ratings
or view top-rated stocks.

What is Regulus Therapeutics' stock price forecast for 2023?

2 brokerages have issued twelve-month price targets for Regulus Therapeutics' stock. Their RGLS share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 720.3% from the stock's current price.
View analysts price targets for RGLS
or view top-rated stocks among Wall Street analysts.

How have RGLS shares performed in 2023?

Regulus Therapeutics' stock was trading at $1.37 at the start of the year. Since then, RGLS stock has decreased by 6.6% and is now trading at $1.28.
View the best growth stocks for 2023 here
.

When is Regulus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RGLS earnings forecast
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02.

When did Regulus Therapeutics' stock split?

Regulus Therapeutics shares reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.58%), Renaissance Technologies LLC (0.24%), Prelude Capital Management LLC (0.21%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends
.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $1.28.

How much money does Regulus Therapeutics make?

Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $24.93 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-28,320,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.regulusrx.com. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at ccalsada@regulusrx.com.

This page (NASDAQ:RGLS) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -